US › Healthcare

Q32 Bio Inc (QTTB)

US · Healthcare · Biotechnology

$16.16+6.53%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-7.6M

Profit YoY

+31.0%

EPS

$-0.54

EPS estimate

$-0.68

EPS came in at -0.54 against a street estimate of -0.68 — a beat of 20.6%.

Key statistics

Market cap

$465.8M

P/E

5.6

Forward P/E

0.0

P/B

10.05

Book value

$3.17

EPS (TTM)

$2.78

52-week high

$23.57

52-week low

$1.57

50-day MA

$13.02

200-day MA

$6.46

Beta

-0.27

Analyst view

Analysts rate Q32 Bio Inc a buy (1 buy, 2 hold, 0 sell out of 3) with an average price target of $44.50.

Shareholding

Insiders

3.17%

Institutions

74.37%

Largest institutional holders

Fund	Stake
Orbimed Advisors, LLC	7.57%
Atlas Venture Life Science Advisors, LLC	7.03%
Opaleye Management Inc	4.22%
The Carlyle Group Inc	3.70%
ARCH VENTURE CORP	1.08%
Vanguard Capital Management, LLC	1.03%
Mackenzie Investments	0.83%
Sanofi	0.82%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Q32 Bio Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.